Prevalence and treatment of anti-NMDA receptor encephalitis

The Lancet Neurology

Volumn 12, Issue 5, 2013, Pages 424-425

  Liba, Zuzana ^a   Sebronova, Vera ^a   Komarek, Vladimir ^a   Sediva, Anna ^a   Sedlacek, Petr ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; RITUXIMAB; AUTOANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE; LETTER; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CEREBROSPINAL FLUID; FEMALE; IMMUNOLOGY; MALE; METHODOLOGY; NOTE;

ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84876482783     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70070-X     Document Type: Letter

References (5)

1. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12:157-165.
2. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R Clinical experience and laboratory investigation in patients with anti-NMDA encephalitis. Lancet Neurol 2011, 10:63-74.
3. Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009, 118:737-743.
4. Peery HE, Day GS, Dunn S, et al. Anti-NMDA receptor encephalitis the disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012, 11:863-872.
5. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010, 133:2232-2247.